Key result
Anticoagulation linked to ~25% lower all-cause mortality in octogenarians with AF.
Why the study?
The benefits and risks of anticoagulation therapy in patients aged ≥ 80 years with AF remain underexplored because this population is underrepresented in randomized clinical trials.
Does oral anticoagulation therapy reduce all-cause mortality in adults aged 80 years and older with non-valvular atrial fibrillation?
Cohort (n=45,305)
Yes
Does oral anticoagulation therapy reduce all-cause mortality in adults aged 80 years and older with non-valvular atrial fibrillation?
In adults aged 80 years and older with atrial fibrillation, continued anticoagulation therapy was associated with a 25% lower hazard of all-cause mortality despite higher rates of gastrointestinal bleeding and comparable intracranial hemorrhage rates, supporting anticoagulation in appropriately selected very elderly patients.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In this real-world dataset, these results highlight the continued benefit of anticoagulation in this high-risk group, despite heightened bleeding concerns, in reducing mortality. [The study] findings support continued anticoagulation in appropriately selected older patients, rather than withholding therapy on the basis of age alone.”
May support anticoagulation consideration in selected octogenarians with AF despite GI bleeding; leaves open confirmation by randomized trials.
Background The benefits and risks of anticoagulation therapy in patients aged ≥ 80 years with atrial fibrillation (AF) remain underexplored, as this population is underrepresented in randomized clinical trials. We evaluated mortality and bleeding outcomes associated with anticoagulation use in this population. Design We conducted a retrospective cohort study using MDClone, a synthetic electronic health record database from a large US health system, including 45,305 patients aged ≥ 80 years with AF after excluding those with mitral stenosis, mechanical heart valves, cirrhosis, or end-stage renal disease. Patients were categorized as continued, initiated, discontinued, or never anticoagulated. The primary outcome was all-cause mortality at 30 days, 6 months, 1 year, and 5 years; secondary outcomes were ischemic stroke, gastrointestinal bleeding (GIB), and intracranial hemorrhage (ICH). To address immortal time bias, the primary analysis used a time-varying Cox model, complemented by a 90-day landmark analysis and propensity score matching. Key Results Patients who continued anticoagulation had lower 1-year mortality than those never anticoagulated (8.7% vs 17.7%; p < 0.001). In the time-varying Cox model, anticoagulation was associated with a 25% lower hazard of mortality (HR 0.75, 95% CI 0.71–0.79). Compared with continued anticoagulation, mortality was higher among patients who initiated (HR 1.51, 95% CI 1.38–1.66), discontinued (HR 1.64, 95% CI 1.49–1.81), or never received anticoagulation (HR 2.22, 95% CI 2.05–2.41), and persisted after propensity score matching. At 5 years, mortality converged across groups. GIB was more frequent in anticoagulated patients (continued 13.0%, initiated 11.9%), whereas ICH rates were low and comparable across groups (1.3–1.6%, p = 0.129). Conclusions Among patients aged ≥ 80 years with AF, anticoagulation therapy was associated with lower all-cause mortality despite an increase in gastrointestinal bleeding. These findings support continued anticoagulation in appropriately selected elderly patients, rather than withholding therapy on the basis of age alone.
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2026) conducted a cohort in Non-valvular atrial fibrillation (n=45,305). Anticoagulation therapy (warfarin, apixaban, rivaroxaban, edoxaban, dabigatran) vs. No anticoagulation (or time-updated off anticoagulation) was evaluated on All-cause mortality (time-varying Cox model and 1-year mortality in Continued vs Never groups) (HR 0.75, 95% CI 0.71-0.79, p=<0.001). Anticoagulation therapy was associated with a 25% lower hazard of all-cause mortality in adults aged ≥80 years with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: